Xin Lang Cai Jing·2025-11-10 03:04Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating high levels of financing and short selling [1][2] Group 2 - On November 7, Junshi Biosciences' stock fell by 1.92%, with a trading volume of 292 million yuan. The financing buy-in amount was 2.023 million yuan, while the financing repayment was 26.51 million yuan, resulting in a net financing buy of -627.79 thousand yuan [1] - As of November 7, the total financing and securities lending balance for Junshi Biosciences was 1.402 billion yuan, with the financing balance at 1.389 billion yuan, accounting for 4.80% of the circulating market value, which is above the 90th percentile level over the past year [1] - On the same day, Junshi Biosciences repaid 1,490 shares in securities lending and sold 2,000 shares, with a selling amount of 75.6 thousand yuan. The remaining securities lending volume was 32.85 thousand shares, with a balance of 12.4132 million yuan, also above the 90th percentile level over the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs. The main revenue sources are 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2] - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [2] - As of September 30, 2025, the top ten circulating shareholders included E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF, with both funds reducing their holdings compared to the previous period [2]